Factors associated with disease-free and abdominal recurrence-free survival in abdominopelvic and retroperitoneal sarcomas.
abdominal RFS
disease-free survival
liposarcoma
radiation
retroperitoneal sarcoma
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
07
02
2022
accepted:
14
02
2022
pubmed:
4
3
2022
medline:
17
5
2022
entrez:
3
3
2022
Statut:
ppublish
Résumé
Retroperitoneal and abdominopelvic sarcomas are rare heterogeneous malignancies. The only therapy proven to improve disease-free survival (DFS) is R0/R1 surgical resection. We sought to analyze whether additional factors such as radiation and systemic therapy were associated with DFS and abdominal recurrence-free survival (RFS). Retrospective review of adults (≥18) with resectable abdominopelvic and retroperitoneal sarcomas who underwent intent-to-cure surgery at a high-volume tertiary referral center between 1998 and 2015. The main outcome measures were DFS and abdominal RFS. Overall, 159 patients met the criteria for inclusion. Median follow-up was 4.8 years (range 0.1-18.9 years). The most common histology was liposarcoma (49%). Systemic therapy was administered to 48% of patients and was not associated with improved outcomes. The neoadjuvant radiotherapy group (11%) had improved adjusted DFS (5.46 years, 95% CI [3.68, 7.24] vs. 3.1 years, 95% CI [2.48, 3.73]) and abdominal RFS (6.14 years, 95% CI [4.38, 7.89] vs. 3.22 years, 95% CI [2.61, 3.84]). The adjuvant radiotherapy group (19%) had no improvement. In a cohort of patients undergoing resection for retroperitoneal or abdominopelvic sarcoma, neoadjuvant radiation improved DFS and abdominal RFS. A follow-up of over three years was needed to appreciate a difference in outcomes.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Retroperitoneal and abdominopelvic sarcomas are rare heterogeneous malignancies. The only therapy proven to improve disease-free survival (DFS) is R0/R1 surgical resection. We sought to analyze whether additional factors such as radiation and systemic therapy were associated with DFS and abdominal recurrence-free survival (RFS).
METHODS
METHODS
Retrospective review of adults (≥18) with resectable abdominopelvic and retroperitoneal sarcomas who underwent intent-to-cure surgery at a high-volume tertiary referral center between 1998 and 2015. The main outcome measures were DFS and abdominal RFS.
RESULTS
RESULTS
Overall, 159 patients met the criteria for inclusion. Median follow-up was 4.8 years (range 0.1-18.9 years). The most common histology was liposarcoma (49%). Systemic therapy was administered to 48% of patients and was not associated with improved outcomes. The neoadjuvant radiotherapy group (11%) had improved adjusted DFS (5.46 years, 95% CI [3.68, 7.24] vs. 3.1 years, 95% CI [2.48, 3.73]) and abdominal RFS (6.14 years, 95% CI [4.38, 7.89] vs. 3.22 years, 95% CI [2.61, 3.84]). The adjuvant radiotherapy group (19%) had no improvement.
CONCLUSIONS
CONCLUSIONS
In a cohort of patients undergoing resection for retroperitoneal or abdominopelvic sarcoma, neoadjuvant radiation improved DFS and abdominal RFS. A follow-up of over three years was needed to appreciate a difference in outcomes.
Identifiants
pubmed: 35239187
doi: 10.1002/jso.26828
pmc: PMC9313796
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1292-1300Informations de copyright
© 2022 The Authors. Journal of Surgical Oncology published by Wiley Periodicals LLC.
Références
J Clin Oncol. 2013 May 1;31(13):1649-55
pubmed: 23530096
J Surg Oncol. 2018 Jan;117(1):33-41
pubmed: 29315649
Ann Surg Oncol. 2012 Sep;19(9):2981-91
pubmed: 22476756
Lancet Oncol. 2016 Jul;17(7):966-975
pubmed: 27210906
Am J Clin Oncol. 2018 Mar;41(3):274-279
pubmed: 26703813
Radiol Oncol. 2020 Feb 29;54(1):14-21
pubmed: 32114526
Ann Surg Oncol. 2016 Oct;23(11):3531-3540
pubmed: 27480354
J Surg Oncol. 2019 Sep;120(3):340-347
pubmed: 31246290
J Clin Oncol. 1996 Mar;14(3):859-68
pubmed: 8622034
Ann Surg. 2015 Jul;262(1):163-70
pubmed: 25185464
Adv Radiat Oncol. 2017 Jan 04;2(1):85-93
pubmed: 28740917
Cancer. 2006 Apr 1;106(7):1610-6
pubmed: 16518798
J Am Coll Surg. 2002 Apr;194(4):436-47
pubmed: 11949749
Surg Oncol. 2014 Sep;23(3):155-60
pubmed: 25085344
J Surg Oncol. 2022 Jun;125(8):1292-1300
pubmed: 35239187
J Clin Oncol. 1998 Jan;16(1):197-203
pubmed: 9440743
Ann Surg. 2016 Mar;263(3):593-600
pubmed: 25915910
Ann Surg. 2016 May;263(5):1002-9
pubmed: 26727100
Surg Oncol. 2019 Jun;29:53-63
pubmed: 31196494
Cancer. 2016 May 1;122(9):1417-24
pubmed: 26916507
Lancet Oncol. 2020 Oct;21(10):1366-1377
pubmed: 32941794
Ann Surg. 2003 Sep;238(3):358-70; discussion 370-1
pubmed: 14501502
Acta Oncol. 2014 Sep;53(9):1165-72
pubmed: 25000415
Eur J Surg Oncol. 2018 May;44(5):571-579
pubmed: 29472043